Edison Pharmaceuticals Lands $20,000,000 Series F Funding

  • Feed Type
  • Date
    11/27/2012
  • Company Name
    Edison Pharmaceuticals
  • Mailing Address
    350 N. Bernardo Ave. Mountain View, CA 94043
  • Company Description
    Edison’s business is the development of drugs to treat diseases that impair energy metabolism. Energy impairment diseases can be classified on the basis of whether they are inherited or acquired, and furthermore on the location of the defect. Edison is initially focusing on inherited diseases of the mitochondria- nature’s biological energy substation.
  • Website
    http://www.edisonpharma.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $20,000,000
  • Transaction Round
    Series F
  • Proceeds Purposes
    Proceeds will be used to advance the clinical development of EPI-743. The company has recently announced the initiation of phase 2B clinical trials in the United States in two orphan mitochondrial diseases, Leigh syndrome and Friedreich’s ataxia. Additional clinical development initiatives are underway and will be announced in Q1 2013.
  • M&A Terms
  • Venture Investor
    Mitsui & Co.
  • Venture Investor
    Undisclosed

By posting a comment, you agree to our terms and conditions.